



**HAL**  
open science

## **Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study**

Pascale Perfezou, Nolwenn Hall, Jean-Charles Duthe, Basma Abdi, Sophie Seang, Cédric Arvieux, Isabelle Lamaury, Amélie Menard, Anne-Geneviève Marcelin, Christine Katlama, et al.

### ► To cite this version:

Pascale Perfezou, Nolwenn Hall, Jean-Charles Duthe, Basma Abdi, Sophie Seang, et al.. Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study. *Journal of Antimicrobial Chemotherapy*, 2023, 78 (8), pp.1929-1933. 10.1093/jac/dkad185 . hal-04341611

**HAL Id: hal-04341611**

**<https://univ-rennes.hal.science/hal-04341611>**

Submitted on 22 Feb 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Title**

2 **Doravirine plus lamivudine (DOR+3TC) two-drug regimen as a maintenance antiretroviral**  
3 **therapy in people living with HIV: a French observational study**

4

5 **Running title**

6 Doravirine plus lamivudine as a maintenance ART

7

8 **Authors**

9 Pascale PERFEZOU<sup>1</sup>, Nolwenn HALL<sup>1</sup>, Jean-Charles DUTHE<sup>1</sup>, Basma ABDI<sup>2</sup>, Sophie SEANG<sup>3</sup>,  
10 Cédric ARVIEUX<sup>4</sup>, Isabelle LAMAURY<sup>5</sup>, Amélie MENARD<sup>6</sup>, Anne-Geneviève MARCELIN<sup>2</sup>,  
11 Christine KATLAMA<sup>3</sup>, Romain PALICH<sup>3\*</sup>, for the Dat'AIDS study group

12

13 **Affiliations**

14 1. Public Health Center, Quimper Hospital, Quimper, France

15 2. Sorbonne University, Virology Department, Pitié-Salpêtrière Hospital, AP-HP, Pierre  
16 Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France

17 3. Sorbonne University, Infectious Diseases Department, Pitié-Salpêtrière Hospital, AP-  
18 HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris,  
19 France

20 4. Infectious Diseases and Intensive Care Unit, University Hospital, Rennes, France

21 5. Infectious and Tropical Diseases Department, University Hospital of Guadeloupe,  
22 Pointe-à-Pitre, France

23 6. IHU-Méditerranée Infection, Aix Marseille University, AP-HM, Marseille, France

24

25 **Corresponding author**

26 Romain PALICH, MD, PhD

27 Service des Maladies Infectieuses, hôpital Pitié-Salpêtrière, 47-83 boulevard de l'hôpital,

28 75013 Paris, France

29 Tel: +33.1.42.16.01.71, fax: +33.1.42.16.04.45

30 Email: romain.palich@aphp.fr

31

32 **Word count**

33 Abstract: 255

34 Text: 1529

35 **ABSTRACT**

36 **Background.** Two-drug regimens based on integrase strand transfer inhibitors (INSTIs) and  
37 boosted PIs has entered recommended ART. However, INSTIs and boosted PIs may not be  
38 suitable for all patients. We aimed to report our experience with doravirine/lamivudine  
39 (DOR+3TC) as maintenance therapy in PLWH followed in French HIV settings.

40 **Methods.** This observational study enrolled all adults who initiated DOR+3TC between  
41 09/01/2019 and 10/31/2021, in French HIV centers participating in the Dat'AIDS cohort. The  
42 primary outcome was the rate of virological success (plasma HIV-RNA <50 copies/mL) at W48.  
43 Secondary outcomes included: rate of treatment discontinuation for non-virological reasons,  
44 evolution of CD4 count and CD4/CD8 ratio over follow-up.

45 **Results.** Fifty patients were included, with 34 (68%) men, median age: 58 years (IQR 51-62),  
46 ART duration: 20 years (13-23), duration of virological suppression: 14 years (8-19), CD4 count:  
47 784/mm<sup>3</sup> (636-889). Prior switching, all had plasma HIV-RNA <50 copies/mL. All but three  
48 were naive to doravirine, and 36 (72%) came from a three-drug regimen. Median follow-up  
49 was 79 weeks (IQR 60-96). Virological success rate at W48 was 98.0% (95%CI 89.4-99.9). One  
50 VF occurred at W18 (HIV-RNA=101 copies/mL) in a patient who briefly discontinued DOR+3TC  
51 due to intense nightmares; no resistance at baseline; no resistance emergence. There were  
52 three strategy discontinuations for adverse event (digestive disorders: n=2, insomnia: n=1).  
53 There was no significant change in CD4/CD8 ratio, while CD4 T-cell count significantly  
54 increased.

55 **Conclusion.** These preliminary findings suggest that DOR+3TC regimen can maintain high  
56 levels of viral suppression in highly ART-experienced PLWH with long-term viral suppression,  
57 and good CD4+T cells count.

## 58 INTRODUCTION

59 Although current antiretroviral treatments have improved in terms of efficacy, robustness,  
60 genetic barrier to resistance and tolerability, people living with HIV (PLWH) remain exposed  
61 to drug toxicity for several decades. Two-drug regimens (2DRs) are now recommended in  
62 international guidelines as maintenance regimens for virally suppressed PLWH to limit long-  
63 term cumulated toxicity of certain drugs.<sup>1,2</sup> Recommended 2DRs include oral boosted-  
64 PI/lamivudine (bPI/3TC), dolutegravir/lamivudine (DTG/3TC) and dolutegravir/rilpivirine  
65 (DTG/RPV), and injectable cabotegravir+rilpivirine (CAB+RPV). However, not all PLWH are able  
66 to receive integrase strand transfer inhibitor- (INSTI-) or bPI-based 2DRs, in the event of past  
67 intolerance, resistance or drug-drug interaction.

68 2DRs not based on INSTIs or bPIs could be a suitable treatment option in these patients, but  
69 data to support this are almost non-existent. Until now, only one, small pilot study has  
70 evaluated the virological efficacy of a 2DR based on an NNRTI plus an NRTI. In 2020, Kahlert,  
71 *et al.* demonstrated that nevirapine/lamivudine (NVP/3TC) was able to maintain control of  
72 viral replication (plasma HIV-RNA <50 copies/mL) in 19 patients over 144 weeks.<sup>3</sup>

73 Doravirine is a new generation NNRTI with very few drug interactions and a better genetic  
74 barrier than older NNRTIs. It has been approved in Europe for treatment-naïve and treatment-  
75 experienced PLWH, following large trials that demonstrated its virological efficacy and good  
76 safety profile.<sup>4-6</sup> Its combination with lamivudine, as a 2DR, has never been investigated.

77 Although not a recommended strategy, some patients have received DOR+3TC because of  
78 their virological and therapeutic history. Herein, we aimed to report the reasons for switching,  
79 as well as the ability of DOR+3TC to maintain virological control in PLWH followed in five  
80 French centers.

81

## 82 **METHODS**

83 Information was collected from centers participating in the French Dat'AIDS cohort  
84 (Clinicaltrials.gov reference: NCT02898987) after approval by the Nantes Institutional Review  
85 Board and the French National Committee on Informatics and Human Rights (CNIL number:  
86 1357652). The Dat'AIDS cohort is an ongoing cohort, started in 2000, including at that time all  
87 PLWH with their previous medical history, and all new PLWH in care since then have become  
88 part of the cohort, after they were fully informed and provided written consent.<sup>7</sup>

89 This observational, non-interventional study included all adults who switched to DOR+3TC  
90 between 09/01/2019 and 01/31/2022, with at least 24 weeks of follow-up at time of analysis,  
91 in 5 HIV centers (i.e., centers with at least one patient meeting the inclusion criteria): Quimper,  
92 Pitié-Salpêtrière (Paris), Rennes, Pointe-à-Pitre and Marseille. ART prescriptions were made  
93 during routine follow-up by HIV physicians, and were not part of any protocol. However, all  
94 these prescriptions were discussed in local ART committees, independently of this analysis.  
95 There were no additional biological sample or questionnaire used for this study. Past HIV-RNA  
96 and HIV-DNA resistance genotypes were collected, and the cumulative genotype combined all  
97 past genotypic tests with an updated interpretation using the latest version of the ANRS  
98 algorithm ([www.hivfrenchresistance.org](http://www.hivfrenchresistance.org)). We also collected the reasons associated with the  
99 switch to DOR+3TC.

100 The primary outcome was maintenance of virological suppression (HIV-RNA <50 copies/mL)  
101 at W48. Virological failure [VF] was defined as a confirmed HIV-RNA ≥50 copies/mL, or a single  
102 HIV-RNA ≥200 copies/mL, or ≥50 copies/mL with ART change. Secondary outcomes included:  
103 strategy success rate (no VF and no ART change for non-virological reasons), number of ART  
104 discontinuations, emergence of genotypic resistance in the event of VF, evolution of CD4 T-  
105 cell counts and CD4/CD8 ratio over follow-up.

106 Changes in body weight, CD4 T-cell counts and CD4/CD8 ratio were assessed using the  
107 Wilcoxon test. Statistical tests were processed using STATA v.14.

108

## 109 **RESULTS**

110 Fifty patients switched for DOR+3TC, including 41 who reached 48 weeks of follow-up. Median  
111 follow-up was 79 weeks (IQR 60-96). Patients' characteristics are detailed in Table 1. Thirty-  
112 four of them (68%) were men. Median age was: 58 years (IQR 51-62), ART duration: 20 years  
113 (IQR 13-23), duration of virological suppression: 14 years (IQR 8-19), CD4 T-cell count:  
114 784/mm<sup>3</sup> (IQR 636-889). All had plasma HIV-RNA <50 copies/mL at study entry. Prior to  
115 switching, all except three were naive to doravirine, and 36 (72%) were receiving a three-drug  
116 regimen (3DR). Genotypic data (past RNA and DNA resistance genotypes) were available for  
117 20 patients, with no resistance to both doravirine and lamivudine in 18 patients, and a past  
118 M184V mutation in 2 patients, conferring resistance to lamivudine. The M184V mutations  
119 were found on an RNA resistance genotype performed 9 and 11 years prior to switch, in two  
120 patients with prolonged durations of viral suppression before switching (8 and 11 years,  
121 respectively).

122 The main reason for physicians to switch ART to DOR+3TC was to reduce the drug burden, and  
123 to prevent long-term toxicities and drug interactions, in 32 patients with long term viral  
124 suppression (>10-15 years) on stable 3DR. Six patients had adverse events to ongoing ART,  
125 motivating an immediate switch to DOR+3TC: osteoporotic bone fracture on tenofovir  
126 disoproxil fumarate (TDF) (n=2), fast weight gain on INSTI (n=2), digestive discomfort on  
127 rilpivirine (n=1), and myalgia with increased CPK levels on bictegavir (n=1). Twelve presented  
128 a significant drug interaction, motivating an immediate switch to DOR+3TC: rilpivirine and  
129 proton pump inhibitor (n=7), and bPI and comedications (n=5). In addition to those reasons,

130 the use of certain antiretroviral classes needed to be avoided, due to past side effects,  
131 restricting treatment options: weight gain under INSTI with or without tenofovir alafenamide  
132 (TAF) (n=10), weight gain under TAF with no associated INSTI (n=1), neuropsychic intolerance  
133 under INSTI (n=7), marked lipodystrophy attributable to past NRTIs (n=3).

134 One VF occurred at W18 (plasma HIV-RNA=101 copies/mL), leading to a virological success  
135 rate of 98.0% (95%CI 89.4-99.9) at W48 (Figure 1a). This VF occurred in a patient who briefly  
136 stopped his treatment due to intense nightmares. There was no resistance at baseline, and no  
137 resistance emerged had time of VF (HIV-RNA successfully amplified). The patient achieved a  
138 plasma HIV-RNA <50 copies/mL after resumption of boosted PI monotherapy. There were  
139 three other strategy discontinuations over the entire study period for adverse event (digestive  
140 disorder: n=2, insomnia: n=1), leading to a strategy success rate of 92.0% (95%CI 80.8-97.8) at  
141 W48 (Figure 1b).

142 There was no significant change in the body weight (-0.1 kg, p=0.83), the CD4/CD8 ratio (+0.01,  
143 p=72), and we observed a significant increase in the CD4 T-cell counts (+51/mm<sup>3</sup>, p=0.031)  
144 over the study period.

145

## 146 **DISCUSSION**

147 We reported a series of 50 PLWH with a long duration of viral suppression, who were switched  
148 by their HIV physician to DOR+3TC, with high level of virological success (98%) at W48. Only  
149 one VF occurred, in a patient who briefly discontinued DOR+3TC, as attested by low-level of  
150 plasma HIV-RNA. Importantly, there was no emergence of resistance at time of virological  
151 rebound. All other PLWH remained virally controlled. There was no decrease in CD4 T-cell  
152 counts or CD4/CD8 ratio on DOR+3TC, as previously shown in larger studies evaluating other  
153 2DRs as maintenance regimens.<sup>8-11</sup> The DOR+3TC combination was well tolerated, particularly



154 with regard to weight, with no significant variation over the study period.

155 All prescriptions were made in real-life conditions, outside of any protocolized trial. This  
156 explains why the characteristics of the patients are fairly different from those of the  
157 participants usually included in clinical trials. Although they had high current CD4 T-cell counts  
158 ( $>700/\text{mm}^3$ ), associated with a long duration of viral suppression (14 years), 22% of them had  
159 an AIDS-related event in their history. We assume that a significant number of them received  
160 toxic and ineffective antiretroviral combinations at the start of treatment. The main reasons  
161 for choosing DOR+3TC mentioned by clinicians were past or present side effects and drug  
162 interactions. These are indeed two major concerns in the daily practice of managing aging  
163 PLWH.

164 Two-drug suppressive therapies are increasingly important in a context of lifelong required  
165 ART.<sup>12</sup> The benefit of 2DRs, such as DTG/3TC, DTG/RPV or etravirine/raltegravir (ETR/RAL), has  
166 been demonstrated through improved metabolic, renal and bone biomarkers.<sup>8,9,13</sup> Prevention  
167 of cardiovascular and renal function impairment, as well as bone fracture risk attributable to  
168 ART, is a key concern for PLWH who are all aging. In addition, these strategies avoid most of  
169 the drug interactions. However, all PLWH are not able to receive INSTI-based 2DRs, as  
170 evidenced in the sample of patients presented here, e.g., in cases of neuropsychological  
171 intolerance or weight gain from previous INSTI exposure. Previous studies have shown the  
172 robustness and the good tolerance of doravirine, which did not appear to cause excessive  
173 weight gain, unlike INSTIs and TAF. Real-life data are starting to confirm that doravirine-based  
174 combinations are safe in terms of metabolic and weight issues.<sup>14,15</sup> Finally, the cost of the  
175 DOR+3TC combination, which does not exist as a fixed-dose, is lower than for other usual  
176 2DRs.

177 Our study has some limitations, as it is a retrospective observational study including a limited

178 number of patients. The lack of a comparative arm clearly limits the significance of this  
179 analysis. Many resistance genotypes were missing, as is often the case for patients with a long  
180 history of HIV infection. However, our preliminary findings suggest that DOR+3TC regimen is  
181 able to maintain high levels of viral suppression in selected highly ART-experienced PLWH with  
182 long-term viral suppression, and restored CD4+T cells count. Given the interesting virological  
183 and pharmacological profile of both doravirine and lamivudine, we argue for a larger  
184 comparative maintenance trial evaluating the efficacy of the DOR+3TC combination.

185 **ACKNOWLEDGMENTS**

186 This work was presented as a poster at the HIV Drug Therapy Conference, 2022, Glasgow,  
187 United Kingdom (Abs. P094).

188 Dat'AIDS study Group: Besançon: C. Chirouze, K. Bouiller, F. Bozon, AS. Brunel, L. Hustache-  
189 Mathieu, J. Lagoutte, Q. Lepiller, S. Marty-Quinternet, L. Pépin-Puget, B. Rosolen, N. Tissot.

190 Brest: S. Jaffuel, S. Ansart, Y. Quintric, S. Rezig, L. Quaesaet, P. Gazeau. Clermont-Ferrand: C.  
191 Jacomet, N. Mrozek, C. Theis, M. Vidal, C. Richaud, F. Anglade, L. Sauvat, V. Corbin, C.

192 Aumeran, O. Baud, E. Goncalvez, D. Mazzocolin, A. Mirand, A. Brebion, C. Henquell.

193 Guadeloupe: I. Lamaury, E. Breugnon, A. Chéret, E. Curlier, E. Duvalon, I. Fabre, C. Herrmann-

194 Storck, S. Markowicz, M. Marquet, R. Ouissa, L. Pradat-Paz, K. Samar, B. Tressieres. La Roche

195 sur Yon: D. Merrien, O. Bollangier, D. Boucher, T. Guimard, L. Laine, S. Leautez, M. Morrier, P.

196 Perré, P. Point. La Rochelle: M. Roncato-Saberan, X. Pouget-Abadie, C. Chapuzet, L. Faba.

197 Limoges: JF. Faucher, A. Cypierre, S. Ducroix-Roubertou, H. Durox, C. Genet-Villeger, J. Pascual,

198 P. Pinet, C.Codde, S. Rogez, JB. Woillard, C. Benoist. Lyon: D. Alfaiate, A. Becker, L. Cotte, F.

199 Ader, C. Brochier, F. Brunel-Dalmas, O. Cannesson, A. Conrad, S. Degroodt, T. Ferry, M.

200 Godinot, V. Icard, J.M. Livrozet, D. Makhloufi, T. Perpoin, S. Roux, MA. Trabaud, C. Triffault-

201 Fillit, F. Valour, AS. Batalla, H. Lardot, M. Simon, C. Javaux. Marseille IHU Méditerranée: I.

202 Ravaux, A. Ménard, Y. Belkhir, P. Colson, C. Dhiver, M. Martin-Degioanni, L. Meddeb, M.

203 Mokhtari, A. Motte, H. Tissot-Dupont, C. Toméi. Marseille Ste Marguerite: S. Bréigéon, O.

204 Zaegel-Faucher, H. Laroche, M. Dos Santos, MJ. Ducassou, S. Galie, A. Ivanova, I. Jaquet, V.

205 Obry-Roguet, M. Orticoni, E. Ressiot, AS. Ritleng, S. Benkouiten. Martinique: A. Cabié, S. Abel,

206 B. Bigeard, C. Bidelogne, O. Cabras, L Carnino, L. Cuzin, L. Fagour, A. Gros-Dubois, K. Guitteaud,

207 C. Lahuna, E. Louis-Michel, A. Métais, F Quenard, S. Pierre-François. Metz: C. Robert, Z. Cavalli,

208 L. Bucy, R. Genet, C. Schneifer, P. Perez. Montpellier: J. Reynes, M. Bistoquet, E Delaporte, V.

209 Le Moing, J. Lejeune, N. Meftah, C. Merle de Boever, B. Montes, A. Montoya Ferrer, N. Pansu,  
210 J. Reynes, E. Tuillon. Nancy: B. Lefèvre, M. André, G. Baronnet, S. Bevilacqua, L. Boyer, MP.  
211 Bouillon, A. Charmillon, M. Delestan, C. Emilie, E. Frentiu, F. Goehringer, S. Hénard, E.  
212 Jeanmaire, C. Rabaud, A. Radjabaly-Mandjee. Nantes: F. Raffi, C. Allavena, E. André-Garnier,  
213 A. Asquier-Khati, E. Billaud, C. Biron, B. Bonnet, S. Bouchez, D. Boutoille, C. Brunet-Cartier, M.  
214 Cavellec, C. Deschanvres, Th. Drumel, BJ. Gaborit, M. Grégoire, T. Jovelin, M. Lefebvre, R.  
215 Lecomte, R. Mahot, P. Morineau, E. Paredes, V. Reliquet, A. Soria. Nice: P. Pugliese, S. Bréaud,  
216 M. Buscot, M. Carles, D. Chirio, E. Cua, P. Dellamonica, E. Demonchy, A. De Monte, J. Durant,  
217 S. Ferrando, A. Naqvi, I. Perbost, C. Pradier, B. Prouvost-Keller, K. Risso, I. Touitou, A. Viot, S.  
218 Wehrle-Pugliese. Niort: S. Sunder, K. Schepers, V. Goudet, A. Dos Santos, V. Rzepecki. Orléans  
219 :L. Hocqueloux, G. Béraud, C. Gubavu, V. Legros, C. Mille, F. Peira, T. Prazuck, A. Sève. Paris  
220 APHP Bicêtre: C. Goujard, A. Castro-Gordon, P. David-Chevallier, V. Godard, Y. Quertainmont,  
221 E. Teicher, S. Jaureguiberry. Paris APHP Bichat: V. Joly, C. Charpentier, D. Descamps, M.  
222 Digumber, A. Gervais, J. Ghosn, Z. Julia, R. Landman, S. Lariven, S. Le Gac, F. Louni, N. Peiffer-  
223 Smadja, G. Peytavin, C. Rioux, Y. Yazdanpanah. Paris APHP Necker, Institut Pasteur: C. Duvivier,  
224 K. Amazzough, G. Benabdelmoumen, P. Bossi, G. Cessot, C. Charlier, PH. Consigny, C. De La  
225 Porte Des Vaux, M. Garzaro, E. Gomes-Pires, P. Hochedez, K. Jidar, E. Lafont, F. Lanternier, O.  
226 Lortholary, C. Louisin, J. Lourenco, C. Melenotte, O. Pacoud, P. Parize, F. Ruyno, C. Rouzard,  
227 F. Taieb. Paris APHP Pitié Salpêtrière: R. Palich, MA. Valantin, C. Katlama, A. Faycal, R. Agher,  
228 Y. Dudoit, N. Hamani, N. Qatib, I. Qzaibri, L. Lenclume, L. Schneider, S. Seang, R. Tubiana.  
229 Quimper: N. Hall, P. Perfezou, JC. Duthe, FB. Drevillon, JP. Talarmin, L. Khatchatourian. Reims:  
230 F. Bani-Sadr, JL. Berger, V. Brodard, M. Hentzien, I. Kmiec, D. Lambert, H. Marty, Y. N’Guyen.  
231 Rennes: C. Arvieux, M. Baldeyrou, F. Benezit, JM. Chapplain, M. Dupont, JC. Duthé, S. Ismaël,  
232 T. Jovelin, A. Lebot, F. Lemaitre, D. Luque-Paz, A. Maillard, C. Morlat, S. Patrat-Delon, L. Picard,

233 M. Poisson-Vannier, C. Pronier M. Revest, P. Tattevin, J. Vivent. St Etienne: A. Gagneux-  
234 Brunon, E. Botelho-Nevers, A. Frésard, A. Pouvaret, V. Ronat. Strasbourg: D. Rey, C. Cheneau,  
235 C. Bernard-Henry, E. De Mautort, S. Fafi-Kremer, P. Fischer, P. Gantner, C. Mélounou, A.  
236 Ursenbach, P. Klee, Y. Hansmann, N. Lefebvre, Y. Ruch, F. Danion, B. Hoellinger, T. Lemmet, V.  
237 Gerber, M. Bourne-Watrin. Toulouse: P. Delobel, M. Alvarez, N. Biezunski, X. Boumaza, A.  
238 Debard, C. Delpierre, C. Garnier, L. Lelièvre, G. Martin-Blondel, M. Piffaut, C. Rastoll, K. Saune.  
239 Tourcoing: O. Robineau, E. Aïssi, I. Alcaraz, E. Alidjinou, V. Baclet, L. Bocket, A. Boucher, V.  
240 Derdour, B. Lafon-Desmurs, A. Meybeck, M. Pradier, M. Tetart, M. Valette, N. Viget, A. Diarra.  
241 Vannes: G. Corvaisier, M. Brière, M. De La Chapelle, M. Gousseff, M. Le Goff, M. Thierry.

242

#### 243 **FUNDING**

244 Internal funding was used to carry out this work (data management, Dat'AIDS cohort). Data  
245 collection was part of the routine work in the different centers associated with the Dat'AIDS  
246 cohort.

247

#### 248 **TRANSPARENCY DECLARATION**

249 SS, AGM, CK, and RP have received travel grants and advisory fees from Gilead, ViiV Healthcare  
250 and Merck. AGM declares a conflict of interest with Theratec. CA has received advisory fees  
251 from Gilead and ViiV. PP, NH, JCD, BA, IL and AA have no conflicts of interest to declare.

252

#### 253 **REFERENCES**

254 1. European AIDS Clinical Society. Guidelines for the management of people living with HIV in  
255 Europe - v11.1. 2022. Available at: [https://www.eacsociety.org/media/guidelines-](https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf)  
256 [11.1\\_final\\_09-10.pdf](https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf).

- 257 2. Thompson MA, Horberg MA, Agwu AL, *et al.* Primary Care Guidance for Persons With  
258 Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the  
259 Infectious Diseases Society of America. *Clin Infect Dis* 2021; **73**: e3572–605.
- 260 3. Kahlert CR, Cipriani M, Vernazza P. Novel dual HIV maintenance therapy with nevirapine  
261 plus lamivudine retain viral suppression through 144 weeks-A proof-of-concept study. *PLoS*  
262 *One* 2020; **15**: e0237770.
- 263 4. Orkin C, Squires KE, Molina J-M, *et al.* Doravirine/Lamivudine/Tenofovir Disoproxil  
264 Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in  
265 Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of  
266 the DRIVE-AHEAD Trial. *Clin Infect Dis* 2019; **68**: 535–44.
- 267 5. Molina J-M, Squires K, Sax PE, *et al.* Doravirine versus ritonavir-boosted darunavir in  
268 antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised,  
269 double-blind, non-inferiority, phase 3 trial. *Lancet HIV* 2020; **7**: e16–26.
- 270 6. Johnson M, Kumar P, Molina J-M, *et al.* Switching to Doravirine/Lamivudine/Tenofovir  
271 Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48  
272 Weeks: Results of the DRIVE-SHIFT Trial. *J Acquir Immune Defic Syndr* 2019; **81**: 463–72.
- 273 7. Pugliese P, Cuzin L, Cabié A, *et al.* A large French prospective cohort of HIV-infected patients:  
274 the Nadis Cohort. *HIV Med* 2009; **10**: 504–11.
- 275 8. Aboud M, Orkin C, Podzamczar D, *et al.* Efficacy and safety of dolutegravir–rilpivirine for  
276 maintenance of virological suppression in adults with HIV-1: 100-week data from the  
277 randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. *The Lancet HIV* 2019; **6**:  
278 e576–87.
- 279 9. van Wyk J, Ajana F, Bisshop F, *et al.* Efficacy and Safety of Switching to  
280 Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-

281 Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With  
282 Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.  
283 *Clin Infect Dis* 2020; **71**: 1920–9.

284 10. Llibre JM, Brites C, Cheng C-Y, *et al.* Efficacy and Safety of Switching to the 2-Drug Regimen  
285 Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic  
286 Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results  
287 From the Phase 3, Noninferiority SALSA Randomized Trial. *Clin Infect Dis* 2023; **76**: 720–9.

288 11. Overton ET, Richmond G, Rizzardini G, *et al.* Long-acting cabotegravir and rilpivirine dosed  
289 every 2 months in adults with HIV-1 infection: 152-week results from ATLAS-2M, a  
290 randomized, open-label, Phase 3b, noninferiority study. *Clin Infect Dis* 2023: ciad020.

291 12. Gibas KM, Kelly SG, Arribas JR, *et al.* Two-drug regimens for HIV treatment. *Lancet HIV*  
292 2022; **9**: e868–83.

293 13. Katlama C, Assoumou L, Valantin M-A, *et al.* Dual therapy combining raltegravir with  
294 etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced  
295 HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS  
296 163 ETRAL study. *J Antimicrob Chemother* 2019; **74**: 2742–51.

297 14. Garcia M, Martellosio JP, Giraud V, *et al.* Efficacy and Safety of Doravirine-Based Regimens  
298 in Real Life: A Prospective Monocentric French Study. *AIDS Res Hum Retroviruses* 2022; **38**:  
299 779–81.

300 15. Mazzitelli M, Antoni MD, Castelli F, *et al.* Real-life use of Doravirine in treatment-  
301 experienced people living with HIV: A multicenter Italian study. *Medicine (Baltimore)* 2022;  
302 **101**: e29855.

303

304

305 **Table 1. Patients' characteristics at baseline (N=50).**

<b>Age, years, median (IQR)</b>	58 (51-62)
<b>Gender, n (%)</b>	
- Male	34 (68)
- Female	16 (32)
<b>Birth Country, n (%)</b>	
- France	44 (88)
- Other	6 (12)
<b>Transmission group, n (%)</b>	
- Heterosexual	23 (46)
- MSM	21 (42)
- Other	6 (12)
<b>Comorbidities, n (%)</b>	
- Treated diabetes	6 (12)
- Treated high blood pressure	17 (34)
- Dyslipidemia	22 (44)
- Kidney disease	5 (10)
- Osteoporosis	7 (14)
<b>Body weight, kg, median (IQR)</b>	73.9 (66.3-85.0)
<b>CDC stage C, n (%)</b>	11 (22)
<b>CD4 T-cell nadir, cells/mm<sup>3</sup>, median (IQR)</b>	258 (145-385)
<b>HIV-RNA zenith, log<sub>10</sub> copies/mL, median (IQR)</b>	4.79 (3.67-5.32)
<b>Time from HIV diagnosis, years, median (IQR)</b>	24 (16-29)
<b>Time from ART initiation, years, median (IQR)</b>	20 (13-23)
<b>Previous virological failure on NNRTI, n (%)</b>	0 (0)
<b>Previous virological failure on 3TC or FTC, n (%)</b>	3 (6)
<b>Genotypic sensitivity score to DOR+3TC<sup>a</sup>, n (%)</b>	
- 1	2 <sup>b</sup> /20 (10)
- 2	18/20 (90)
<b>Duration of viral suppression, years, median (IQR)</b>	14 (8-19)
<b>CD4 T-cell count, cells/mm<sup>3</sup>, median (IQR)</b>	784 (636-889)
<b>CD4/CD8 ratio, median (IQR)</b>	1.16 (0.96-1.50)
<b>Antiretroviral strategy prior to DOR+3TC, n (%)</b>	
- NNRTI-based 3DR	24 (48)
- INSTI-based 3DR <sup>c</sup>	12 (24)
- Dolutegravir/lamivudine	6 (12)
- Darunavir/ritonavir/lamivudine	3 (6)
- Other 2DR	3 (6)
- Boosted PI monotherapy	2 (4)


306

307 NOTES. 3DR: three-drug regimen. 2DR: two-drug regimen. a. Calculated from cumulative  
 308 historical HIV-RNA and HIV-DNA genotypes with reverse transcriptase available sequences  
 309 (N=20). b. These two patients had a documented M184V mutation in past RNA genotypes, in



310 2010 and 2011. c. These NNRTI-based 3DR included rilpivirine (n=11), nevirapine (n=9),  
311 doravirine (n=3) and efavirenz (n=1).

312 Figure 1. Virological success rate (A), and strategy success rate (B) under DOR+3TC over time.



313